Market Performance - The A-share market experienced a collective increase, with the Shanghai Composite Index rising by 0.18%, the Shenzhen Component Index by 0.09%, and the ChiNext Index by 0.71% [1] - The North Exchange 50 Index saw a slight decline of 0.05% [1] - The total trading volume across the three markets was 29,215 billion yuan, a decrease of 3,592 billion yuan compared to the previous day [1] - Over 1,900 stocks in the three markets closed in the green [1] Sector Performance - The leading sectors in terms of gains included precious metals, semiconductors, cultivated diamonds, photovoltaic equipment, insurance, military equipment, CPO, and AI-related sectors [1] - Conversely, sectors that experienced declines included biopharmaceuticals, coal mining and processing, chemicals, batteries, pork, liquor, tourism and hotels, and power grid equipment [1] ETF Performance - The semiconductor sector showed strong performance, with the Huatai-PB Fund's China-Korea Semiconductor ETF rising by 4.51%, the Huaxia Fund's Sci-Tech Semiconductor ETF by 3.59%, and the Huatai-PB Fund's Sci-Tech Semiconductor Equipment ETF by 3.52% [1] - The Sci-Tech 100 Index saw an afternoon surge, with the Guotai Fund's Sci-Tech 100 ETF increasing by 3.41% [1] - The CPO sector also showed resilience, with the Huabao AI ETF rising by 2.76% [1] - The Guotai 2000 ETF from ICBC fell by 4.93% [1] - The vaccine sector declined, with the vaccine ETF and the vaccine ETF from Fuguo both dropping by 4% [1] - The energy sector weakened, with the coal ETF and energy chemical ETF both decreasing by 2% [1]

Market Overview - The three major A-share indices showed mixed performance in the morning session, with the Shanghai Composite Index up by 0.03%, the Shenzhen Component down by 0.37%, and the ChiNext Index up by 0.44% [1] - The North China 50 Index fell by 1.26%, and the total trading volume in the Shanghai, Shenzhen, and Beijing markets reached 1.89 trillion yuan, a decrease of 372.6 billion yuan compared to the previous day [1] - Over 4,400 stocks in the market experienced declines [1] Sector Performance - The computing power hardware industry chain strengthened, with CPO and memory sectors leading the gains [1] - Gold and semiconductor concept stocks also showed strength, while sectors such as consumer goods, lithium batteries, rare earth permanent magnets, innovative pharmaceuticals, and AI applications weakened [1] ETF Performance - In the ETF market, the semiconductor equipment sector saw significant gains, with the Huaxia Fund's Sci-Tech Semiconductor ETF, the Huatai-PB Fund's Sci-Tech Semiconductor Equipment ETF, and the Penghua Sci-Tech Semiconductor Equipment ETF all rising over 3% [1] - The CPO sector remained resilient, with the Guotai Fund's Communication ETF and the Fuguo Fund's Communication Equipment ETF increasing by 2.31% and 2.27%, respectively [1] - Conversely, the Guotai 2000 ETF from ICBC fell by 7%, and the vaccine sector declined, with the Vaccine ETF and the Fuguo Vaccine ETF both dropping by 5% [1] - The lithium battery sector faced a broad decline, with the Lithium Battery ETF and the Southern Battery ETF both down by 3% [1]

Core Viewpoint - The vaccine sector is experiencing a significant surge, driven by recent developments in vaccine approvals and the increasing demand for vaccination due to an aging population in China [1]. Group 1: Market Performance - The vaccine ETF, 富国 (159645), rose by 3.87% during the trading session, with notable increases in constituent stocks such as 华兰疫苗, which surged by 20%, 万孚生物, which increased by over 17%, and 智飞生物, which rose by over 13% [1]. Group 2: Company Developments - 华兰疫苗 announced that its shingles vaccine has received approval from the National Medical Products Administration for clinical trials, marking a significant breakthrough in its pipeline for important preventive measures [1]. Group 3: Industry Outlook - Long-term projections indicate a substantial growth potential for shingles vaccine demand, driven by the accelerating aging process in the domestic population and increasing vaccine penetration rates [1]. - The acceleration of approval processes for innovative vaccines and increased investment in vaccine research and development, supported by government policies, is expected to foster rapid growth in China's vaccine industry [1]. - The international expansion of vaccine markets, highlighted by recent outbreaks such as the Nipah virus in West Bengal, India, is also broadening the demand landscape for the vaccine industry [1]. Group 4: Investment Opportunities - The vaccine ETF 富国 (159645) closely tracks the 国证疫苗与生物科技指数 (980015), which comprises 50 A-share listed companies involved in the biotechnology sector, reflecting the overall performance of quality listed companies in the vaccine and biotechnology industries [1].

Group 1 - Vaccine-related stocks have shown strong performance, with Zhifei Biological rising over 16%, Watson Bio increasing by more than 11%, and Kangtai Biological up by over 8% [1] - The vaccine-related ETFs have also experienced a rise of approximately 4% [1] Group 2 - Specific ETF performance includes: - Vaccine ETF from Fuguo at 0.727, up by 0.029 (4.15%) - Vaccine ETF from Penghua at 0.705, up by 0.028 (4.14%) - General Vaccine ETF at 0.642, up by 0.023 (3.72%) [2] - Institutions indicate that the long-term growth potential for vaccine demand is significant due to increasing vaccination penetration and an aging population [2] - The acceleration of approval and market entry for innovative domestic vaccines, along with increased investment in vaccine research and supportive policies, is expected to drive rapid development in China's vaccine industry [2]

Group 1 - The 2025 stock ETF fund annual report reveals a significant performance, with the champion fund soaring by 233% during the year [1][3] - The overall industry scale is approaching a new high of 36 trillion yuan [1][3] - The worst-performing funds for the year include Penghua Wine ETF with a decline of 12.2%, Huaan Food and Beverage ETF down by 8.75%, and Yinhua Food ETF decreasing by 8.66% [1][3] Group 2 - Over the past three years, the vaccine ETFs have experienced substantial declines, with the Fuguo Vaccine ETF down by 37.96%, Guotai Vaccine ETF down by 37.68%, and Penghua Wine ETF down by 36.54% [2][4]

Core Insights - The 2025 stock ETF has shown a remarkable performance with a year-to-date increase of 233%, indicating a strong recovery in active equity investments [1][2] - The overall industry scale is approaching a new high of 36 trillion yuan, reflecting significant growth in the investment sector [1][2] Performance Summary - The 2025 stock ETF's performance from 2023 to 2025 has been officially released, highlighting the substantial gains in certain funds [1][2] - Specific ETFs such as the vaccine ETFs have experienced significant declines, with the 富国 vaccine ETF down by 37.96%, the 国泰 vaccine ETF down by 37.68%, and the 鹏华 wine ETF down by 36.54% over the same period [1][2]